RACE ONCOLOGY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.22 AUD | -0.81% |
|
-5.43% | +45.24% |
| 26/03 | Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6% | MT |
| 18/03 | Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 203M 134M 11.17B |
|---|---|---|---|---|---|
| Net income 2024 * | -11M -7.27M -606M | Net income 2025 * | -13M -8.6M -716M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 9.3M 6.15M 513M | Net cash position 2025 * | 33.5M 22.15M 1.85B | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-16.9
x | P/E ratio 2025 * |
-15.1
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.02% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.81% | ||
| 1 week | -5.43% | ||
| Current month | -2.79% | ||
| 1 month | -19.21% | ||
| 3 months | +79.41% | ||
| 6 months | +33.33% | ||
| Current year | +45.24% |
1 week
1.14
1.31
1 month
1.141.74
Current year
0.641.81
1 year
0.641.87
3 years
0.644.04
5 years
0.054.23
10 years
0.054.23
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Tillett
CEO | Chief Executive Officer | - | 22/11 |
| Chief Tech/Sci/R&D Officer | - | 01/23/01 | |
Tim Hammond
CTO | Chief Tech/Sci/R&D Officer | - | 23/23/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Smith
BRD | Director/Board Member | 61 | 29/23/29 |
Borje Andersson
PRN | Corporate Officer/Principal | - | 01/20/01 |
Phillip Lynch
BRD | Director/Board Member | - | 01/20/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 1.22 | -0.81% | 320 374 |
| 02/24/02 | 1.23 | -0.40% | 97,774 |
| 01/24/01 | 1.235 | -1.59% | 65,487 |
| 30/24/30 | 1.255 | -3.46% | 61,513 |
| 29/24/29 | 1.3 | -0.76% | 166,369 |
Delayed Quote Australian S.E., May 03, 2024 at 11:40 am IST
More quotes
Race Oncology Limited is an Australia-based precision oncology company with a Phase II/III cancer drug called Zantrene. Zantrene is a potent small molecule inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. The Company is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers. Zantrene (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and a cardio-protective chemotherapeutic. The Company also has clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in acute myeloid leukemia (AML), breast and ovarian cancers and is investigating its use in these areas.
Calendar
23/08/2024
- Q4 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +45.24% | 134M | |
| -1.22% | 103B | |
| +8.59% | 101B | |
| +4.40% | 23.07B | |
| -12.10% | 22.23B | |
| -4.36% | 18.05B | |
| -39.98% | 17.18B | |
| -10.15% | 16.94B | |
| +6.79% | 14.07B | |
| +39.01% | 12.35B |
- Stock Market
- Equities
- RAC Stock
